Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Merck, J&J's New Hepatitis C Treatments Fetch $31,000 in France

April 5, 2011

Though they are still under review by the European Medicines Agency, two new hepatitis C virus (HCV) treatments are already being prescribed to French patients. In December, telaprevir and boceprevir received special temporary authorization in a program for critically ill patients for whom no other effective treatment is available, said French pharmaceutical regulator AFSSAPS.

Used as a complement to existing HCV treatment, telaprevir, made by U.S.-based Johnson & Johnson and Vertex Pharmaceuticals Inc., and boceprevir, by Merck & Co., boost cure rates from roughly half of patients to between two-thirds and three-quarters, studies show. Both drugs are

View Full Article


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

 
See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More on Hepatitis C Drugs in Development

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement